Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Human Blood Cell Disorders Tissue Bank

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2013 by North Shore Long Island Jewish Health System
Sponsor:
Information provided by (Responsible Party):
North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier:
NCT00902447
First received: May 13, 2009
Last updated: August 8, 2013
Last verified: August 2013
  Purpose

The Human Blood Cell Disorder Tissue Bank will provide a convenient, comprehensive source of tissue containing populations of human blood cells from patients with various types of lymphoid, myeloid, and erythroid proliferative diseases as well as other associated conditions. The tissue bank will continue to be an invaluable asset for understanding of the biology of multiple blood cell disorders involving several cell types as well as the physiology of normal cellular counterparts affected in these disorders. Internal and external investigators will be able to utilize this tissue to test hypotheses relating to the immunologic, virologic, genetic, and molecular properties of these abnormal cells as well as normal cells from normal unaffected family members or normal aged matched subjects to provide better comparisons.


Condition
Human Blood Cell Disorders

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Human Blood Cell Disorders Tissue Bank

Further study details as provided by North Shore Long Island Jewish Health System:

Primary Outcome Measures:
  • Accumulate tissue from patients with various blood disorders, including but not restricted to lymphoproliferative, myeloproliferative, and erythroproliferative conditions. [ Time Frame: Indefinite ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Develop a database of at least 10,000 subjects who have donated samples for research as well as DNA banking, and who are willing to be contacted again for consideration of additional studies in the future. [ Time Frame: Indefinite ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

cells, tissue, serum, saliva, etc


Estimated Enrollment: 10000
Study Start Date: April 2009
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts
Human Blood Cell Disorders
Human Blood Cell Disorders Tissue Bank

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Community sample

Criteria

Inclusion Criteria:

  • Participants or participant's Legally Authorized Representatives (LAR) must be able to understand and render voluntary, written informed consent.
  • Patients must be able to contribute the required amount of blood and/or tissue without compromising their well-being or care.
  • Participants must be willing to be contacted again for consideration of additional studies in the future, such as a blood draw or another action (e.g., bone marrow aspiration and/or biopsy) that would be done as part of their standard of care.

Exclusion Criteria:

  • Patients who are known to be anemic, with hemoglobin <8.0g/dl.
  • Patients who are known to be infected with HIV.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00902447

Contacts
Contact: Yasmine Kieso, MSCR 516-562-0391 ykieso@nshs.edu

Locations
United States, New York
The Feinstein Institute for Medical Research Recruiting
Manhasset, New York, United States, 11030
Contact: Yasmine Kieso, MSCR    516-562-0391    ykieso@nshs.edu   
Principal Investigator: Nicholas Chiorazzi, M.D.         
Sponsors and Collaborators
North Shore Long Island Jewish Health System
Investigators
Principal Investigator: Nicholas Chiorazzi, M.D. The Feinstein Institute for Medical Research
  More Information

No publications provided

Responsible Party: North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier: NCT00902447     History of Changes
Other Study ID Numbers: 08-202
Study First Received: May 13, 2009
Last Updated: August 8, 2013
Health Authority: United States: Federal Government

Keywords provided by North Shore Long Island Jewish Health System:
Human Blood Cell Disorders

Additional relevant MeSH terms:
Disease
Pathologic Processes

ClinicalTrials.gov processed this record on November 19, 2014